AJOVista LLC Invests $77,000 in ADMA Biologics, Inc. (NASDAQ:ADMA)

AJOVista LLC bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 17,018 shares of the biotechnology company’s stock, valued at approximately $77,000.

A number of other hedge funds have also added to or reduced their stakes in ADMA. Arizona State Retirement System boosted its holdings in shares of ADMA Biologics by 4.9% during the 4th quarter. Arizona State Retirement System now owns 59,728 shares of the biotechnology company’s stock worth $270,000 after buying an additional 2,769 shares during the period. Cambridge Investment Research Advisors Inc. grew its position in ADMA Biologics by 31.3% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 15,000 shares of the biotechnology company’s stock worth $54,000 after buying an additional 3,572 shares in the last quarter. Swiss National Bank lifted its position in shares of ADMA Biologics by 1.0% during the 3rd quarter. Swiss National Bank now owns 439,800 shares of the biotechnology company’s stock valued at $1,574,000 after acquiring an additional 4,300 shares during the period. Victory Capital Management Inc. raised its stake in ADMA Biologics by 23.0% in the fourth quarter. Victory Capital Management Inc. now owns 29,192 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 5,465 shares in the last quarter. Finally, Raymond James & Associates grew its stake in ADMA Biologics by 2.3% during the fourth quarter. Raymond James & Associates now owns 249,296 shares of the biotechnology company’s stock worth $1,127,000 after buying an additional 5,657 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

Insider Activity at ADMA Biologics

In other news, Director Steve Elms sold 407,000 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total transaction of $2,527,470.00. Following the transaction, the director now owns 3,208,671 shares in the company, valued at $19,925,846.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 639,895 shares of company stock worth $3,927,169 in the last quarter. Company insiders own 6.00% of the company’s stock.

ADMA Biologics Stock Performance

ADMA traded up $0.07 during midday trading on Friday, hitting $6.81. 2,985,668 shares of the company were exchanged, compared to its average volume of 2,092,217. The firm’s 50 day moving average price is $6.21 and its 200-day moving average price is $5.00. ADMA Biologics, Inc. has a 1-year low of $3.06 and a 1-year high of $6.81. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The firm had revenue of $73.90 million during the quarter, compared to the consensus estimate of $73.50 million. On average, research analysts predict that ADMA Biologics, Inc. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Mizuho lifted their price objective on shares of ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and issued a $7.50 price objective (up from $6.00) on shares of ADMA Biologics in a research note on Tuesday, March 26th. Finally, Cantor Fitzgerald boosted their target price on ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ADMA Biologics presently has a consensus rating of “Buy” and an average price target of $7.88.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.